Platform/Pipeline

We are harnessing a unique tumor-immune co-culture system fully integrated with CRISPR that will allow:

  • Discovery of cancer biomarker, synthetic lethality, and resistant mutations for immuno-oncology (I/O) drugs as well as other cancer drugs

  • Systematic discovery of novel cancer drug targets (both Tumor-intrinsic and I/O drug targets)

Platform concept.png

We Aspire to Revolutionize Cancer Drug Development

MEDiC Life Sciences’s Pipeline and Partnerships

Are you interested in developing first-in-class oncology drugs by harnessing the novel targets offered through the MEDiC Life Sciences’s platform? Or have you already developed therapeutic drugs seeking to identify novel biomarkers for the drug, or to discover biomarkers linked to drug-resistant mutations for drug-resistant patient populations? MEDiC Life Sciences is ready to discuss a variety of different collaboration possibilities across MEDiC Life Sciences's platform partnerships and drug co-development programs. Please contact us at info@medicls.com and let us know how we can work together.